Portfolio context · Hainan Hailing
Hainan Hailing Products: Public Portfolio Context
A supplied catalogue can help frame a first non-confidential conversation. It cannot establish a product’s current approval, availability, supply, project acceptance or market fit.
Choose the evidence route for your question
- Which China approval-number fields are publicly recorded? Start with the dated China public product-record snapshot. Match the exact product and entity; a snapshot is not a current approval or availability confirmation.
- Could an injectable project fit the manufacturing pathway? Use the sterile injectable CMO/CDMO assessment route. A catalogue entry does not decide product, site, process, quality or commercial fit.
- What evidence should an overseas reviewer ask for? Read the China GMP and product-specific CoPP guide. General certificate guidance does not establish that a named Hailing product holds a certificate or target-market approval.
Keep these three decisions separate. For an initial discussion, share only the public product name, dosage form or presentation, target market and decision sought—not confidential technical files.
1. What the supplied catalogue says
The bilingual Hainan Hailing product catalogue supplied to this site is dated May 2026. It organizes product entries principally by topical preparations, oral preparations and injection preparations, and also groups entries by therapeutic areas. Anti-infective categories are prominent, alongside other therapeutic areas.
This page intentionally preserves that broad orientation rather than reproducing every product name, strength and packaging entry. A portfolio document can change and may contain market-, legal-entity- or status-sensitive information. For current publicly listed manufacturing scope and the limits of public evidence, see the public evidence and verification boundary.
2. Download the supplied May 2026 product catalogue
Download the bilingual product catalogue (PDF, 159 KB)
This is an exact copy of the company-supplied May 2026 catalogue. It is provided as a portfolio orientation document, not as a current approval-number register, product label, offer, supply statement, site assignment or project-acceptance statement.
3. What it can support in a first screen
A prospective partner can use the dosage-form map to state the first decision clearly: whether to explore a topical, oral or injectable route, and whether the intended therapeutic area and presentation warrant a controlled next-step review. For sterile projects, use the dedicated sterile injectable CMO/CDMO orientation; it explains why a platform statement alone is not product readiness.
- Topical: define presentation, target country and public product status to be checked.
- Oral: define dosage form, release characteristics, presentation and intended regulatory route.
- Injectable: define the sterile strategy, presentation, target market and evidence needed before a project decision.
4. What it cannot establish
A name or dosage form in a catalogue does not confirm that the named product is authorised, marketed, supplied, transferable or suitable in a particular jurisdiction. Nor does it establish which legal entity or site would be relevant to a proposal. Product-specific facts must be matched to the current target-market requirements and reviewed under appropriate confidentiality and governance arrangements.
For examples of how dated, product-specific public records should be read without overreach, see Hainan Hailing overseas registration records. A dated public record and a current commercial or regulatory conclusion are different things.
5. Dated public-record cross-checks
The supplied catalogue can be made more useful without turning it into a current offer: match individual entries to a named, dated public record, then retain the record’s original scope. The examples below are intentionally narrow.
- Latamoxef Sodium for Injection: the National Healthcare Security Administration’s GY-YD2024-2 proposed-selection results table records Hainan Hailing Chemipharma with an injectable 0.25 g × 1 presentation within that specified procurement process. Read the dedicated public-record guide for the evidence boundary.
- Luliconazole Cream: Qinghai’s 2024 appendix “Products included in the alternative drug directory” records Luliconazole Cream, cream dosage form, 1% (10 g:100 mg) and 1 tube, with Hainan Hailing Chemipharma named in its producer and agency fields.
- Piperacillin Sodium for Injection: the same Qinghai appendix records Piperacillin Sodium for Injection, injectable dosage form, 2.0 g and 1 vial, with Hainan Hailing Chemipharma named in those same fields.
- Selected antibacterial injection entries: Tianjin Healthcare Security Administration’s April 2025 information-maintenance table separately records Hainan Hailing Chemipharma as manufacturer for table entries for Piperacillin Sodium for Injection (2.0 g), Ceftazidime for Injection (0.5 g, 1.0 g and 2.0 g), Ceftriaxone Sodium for Injection (1.0 g), and Cefazolin Sodium for Injection (0.5 g and 1.0 g). This is a dated municipal information-maintenance record, not a current product-status or supply statement.
6. How to start a non-confidential discussion
Before an NDA, a concise portfolio inquiry should identify the public generic name, dosage form, presentation, target market, project stage, intended cooperation model, timing assumption and the decision sought. Do not send patient information, complete formulae, detailed processes, unpublished dossiers or trade secrets in first contact.
For a structured first screen, use the non-confidential CMO/CDMO assessment guide, then contact stevenyiqingli@foxmail.com with only the relevant non-confidential context.
7. A clear first question for a product-specific review
To make a first response useful and traceable, keep the question short and non-confidential. State the public generic name, dosage form, strength and presentation, if public, target market, reason for the inquiry and the next decision you need.
“For [public generic name] in [dosage form / public presentation], we are assessing [target market]. Please indicate whether there is a dated public record relevant to the product, and what additional non-confidential information would be needed for a controlled next review.”
This format does not request or create a product offer, current regulatory-status confirmation, supply commitment, manufacturing-site assignment or CMO/CDMO project acceptance. Those points require the appropriate product-, market-, quality-, legal-entity- and project-specific review.
Source and reading boundary
- Hainan Hailing bilingual Product Catalog, May 2026, supplied company source. It is used here for broad portfolio orientation only; it is not presented as an authoritative, current product-status database.
- Steven Li — public evidence and verification boundary.
- Hainan Hailing bilingual corporate presentation, October 2025, supplied company source. One exterior image is used only for visual context; historical operational claims in that presentation are not reproduced or relied upon on this page.
- National Healthcare Security Administration — GY-YD2024-2 proposed-selection results table. It is cited only as a time-bounded procurement-process record.
- Qinghai government — 2024 appendix “Products included in the alternative drug directory”. It is cited only as a dated directory record.
- Sterile injectable CMO/CDMO orientation.
- Tianjin Healthcare Security Administration — April 2025 medical-insurance payment-scope information-maintenance table. It is cited only as a dated municipal information-maintenance record.
Questions prospective partners ask
Does this page confirm that a named product is currently approved, marketed or available?
No. It is a public navigation page based on a May 2026 company-supplied catalogue. Product approval, registration, label, legal entity, site, supply, presentation and current availability must be confirmed separately for each country and product.
Does a dosage-form listing prove that a CMO/CDMO project can be accepted?
No. A dosage-form listing is only a screening input. Product, process, quality, regulatory, legal-entity, site, target-market, capacity and commercial fit require a controlled project-specific review.
What can be shared for an initial portfolio discussion?
Share only non-confidential facts: public generic name, dosage form, presentation, target market, project stage, intended cooperation model, timing assumption and the decision sought. Do not send patient information, complete formulas, detailed processes, unpublished dossiers or trade secrets before an NDA and controlled disclosure plan.
Why does this page not reproduce every product and specification in the supplied catalogue?
A portfolio document can change and may contain market-specific or status-sensitive data. This page preserves the useful dosage-form and therapeutic-area orientation while directing prospective partners to confirm product-specific facts through the appropriate regulatory, quality and commercial review.
What if the Chinese and English catalogue entries differ?
Do not infer equivalence or select one version. Treat the entry as an unresolved screening item until the current product, dosage form, strength, presentation, legal entity, manufacturing site and target-market status are confirmed through the relevant controlled review. This page does not resolve such discrepancies.
How should I frame a first product-specific question?
Keep it non-confidential and specify the public generic name, dosage form, public strength or presentation if known, target market, reason for the inquiry and the next decision sought. Ask whether a dated public record is relevant and what further non-confidential information is needed for a controlled review. This does not create a product offer, regulatory-status confirmation, supply commitment, manufacturing-site assignment or CMO/CDMO project acceptance.
What can this site answer before a controlled review?
It can point to the relevant public evidence boundary, a dated public record where one is identified, and the non-confidential information needed for a next review. It cannot confirm current approval, marketing, supply, capacity, site assignment, price, project acceptance or product suitability in a particular country.
Does the downloadable catalogue provide a current approval-number list?
No. It is a company-supplied May 2026 orientation document. A product-specific approval or marketing conclusion must be verified separately against the applicable current official record using the exact generic name, dosage form, strength, presentation, legal entity and target market.
Which public records are shown on this page?
The page gives a small number of dated, purpose-specific examples from public healthcare-security records and links to the official public drug-data service. These examples do not establish current approval, supply, price, capacity, site assignment, project acceptance or suitability in any country.
Portfolio context · CMO · CDMO